NCT00473174View on ClinicalTrials.gov

Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hypertension
Interventions
DRUG

Ramipril

Dosing on awakening versus bedtime

DEVICE

ambulatory blood pressure monitoring

Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Trial Locations (1)

15701

Hospital Clínico Universitario de Santiago, Santiago de Compostela

All Listed Sponsors
collaborator

King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

University of Vigo

OTHER

NCT00473174 - Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension | Biotech Hunter | Biotech Hunter